- Home
- CISO vs CVKD Comparison
CISO vs CVKD Comparison
Compare CISO & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CISO
- CVKD
- Stock Information
- Founded
- CISO 2015
- CVKD 2022
- Country
- CISO United States
- CVKD United States
- Employees
- CISO N/A
- CVKD N/A
- Industry
- CISO Computer Software: Prepackaged Software
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- CISO Technology
- CVKD Health Care
- Exchange
- CISO Nasdaq
- CVKD Nasdaq
- Market Cap
- CISO 8.3M
- CVKD 17.1M
- IPO Year
- CISO N/A
- CVKD 2023
- Fundamental
- Price
- CISO $0.88
- CVKD $15.24
- Analyst Decision
- CISO
- CVKD Strong Buy
- Analyst Count
- CISO 0
- CVKD 2
- Target Price
- CISO N/A
- CVKD $52.50
- AVG Volume (30 Days)
- CISO 99.5K
- CVKD 59.6K
- Earning Date
- CISO 11-11-2024
- CVKD 11-08-2024
- Dividend Yield
- CISO N/A
- CVKD N/A
- EPS Growth
- CISO N/A
- CVKD N/A
- EPS
- CISO N/A
- CVKD N/A
- Revenue
- CISO $55,807,138.00
- CVKD N/A
- Revenue This Year
- CISO $78.76
- CVKD N/A
- Revenue Next Year
- CISO N/A
- CVKD N/A
- P/E Ratio
- CISO N/A
- CVKD N/A
- Revenue Growth
- CISO 29.55
- CVKD N/A
- 52 Week Low
- CISO $0.26
- CVKD $5.40
- 52 Week High
- CISO $3.60
- CVKD $32.55
- Technical
- Relative Strength Index (RSI)
- CISO 57.14
- CVKD 60.90
- Support Level
- CISO $0.77
- CVKD $11.19
- Resistance Level
- CISO $1.08
- CVKD $15.93
- Average True Range (ATR)
- CISO 0.12
- CVKD 1.36
- MACD
- CISO -0.01
- CVKD 0.23
- Stochastic Oscillator
- CISO 53.55
- CVKD 61.01
About CISO CISO Global Inc.
CISO Global Inc provides cybersecurity services. The services are used to protect client's data, financial information, intellectual property, and business reputation. The services include penetration testing, security remediation, compliance auditing, vulnerability assessment, and others. Geographically, the company operates in U.S., Chile and All other countries. The maximum revenue is generated from U.S.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.